Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces alzheimer disease-like pathology in mice

Microglia play an essential role in innate immunity, homeostasis, and neurotropic support in the central nervous system. In Alzheimer disease (AD), these cells may affect disease progression by modulating the buildup of beta-amyloid (A beta) or releasing proinflammatory cytokines and neurotoxic substances. Discovering agents capable of increasing A beta uptake by phagocytic cells is of potential therapeutic interest for AD. Lipoxin A(4) (LXA(4)) is an endogenous Lipid mediator with potent anti-inflammatory properties directly involved in inflammatory resolution, an active process essential for appropriate host responses, tissue protection, and the return to homeostasis. Herein, we demonstrate that aspirin-triggered LXA(4) (15 mu g/kg) s.c., twice a day, reduced NF-kappa B activation and Levels of proinflammatory cytokines and chemokines, as well as increased levels of anti-inflammatory IL-10 and transforming growth factor-beta. Such changes in the cerebral milieu resulted in recruitment of microglia in an alternative phenotype, as characterized by the up-regulation of YM1 and arginase-1 and the down-regulation of inducible nitric oxide synthase expression. Microglia in an alternative phenotype-positive cells demonstrated improved phagocytic function, promoting clearance of A beta deposits and ultimately leading to reduction in synaptotoxicity and improvement in cognition. Our data indicate that activating LXA(4) signaling may represent a novel therapeutic approach for AD